[ad_1] SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ — CorestemChemon (KOSDAQ: 166480) is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced […]